Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.

MLA

Sugano, Teppei, et al. “Intralymphatic Histiocytosis in a Patient with Lung Adenocarcinoma Treated with Pembrolizumab: A Case Report.” Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, Feb. 2019, p. N.PAG. EBSCOhost, https://doi.org/10.1186/s40425-019-0534-z.

APA

Sugano, T., Seike, M., Funasaka, Y., Yoshida, M., Takayama, R., Okamura, K., Nakanishi, A., Tanaka, T., Takeuchi, S., Noro, R., Minegishi, Y., Kubota, K., Saeki, H., & Gemma, A. (2019). Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report. Journal for ImmunoTherapy of Cancer, 7(1), N.PAG. https://doi.org/10.1186/s40425-019-0534-z

Chicago

Sugano, Teppei, Masahiro Seike, Yoko Funasaka, Mai Yoshida, Ryoko Takayama, Ken Okamura, Asuka Nakanishi, et al. 2019. “Intralymphatic Histiocytosis in a Patient with Lung Adenocarcinoma Treated with Pembrolizumab: A Case Report.” Journal for ImmunoTherapy of Cancer 7 (1): N.PAG. doi:10.1186/s40425-019-0534-z.